- Post-Hoc: China deals are pharma’s new tax inversionsAbout a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...Endpoints · 27d ago↗ source
- Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfrontIpsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...Endpoints · 27d ago↗ source
- Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and moreWelcome back to another edition of Endpoints Weekly! The summer solstice arrives this weekend — the northern hemisphere will reach its maximum tilt toward the sun at 4:24 a.m. Eastern time on Sunda…